Suppression of thrombospondin 1 and 2 production by herpes simplex virus 1 infection in cultured keratocytes

Molecular Vision

Volumn 11, Issue , 2005, Pages 163-168

  Choudhary, Anshoo ^a   Hiscott, Paul ^a   Hart, Charles A ^a   Kaye, Stephen B ^b   Batterbury, Mark ^b   Grierson, Ian ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; IMMEDIATE EARLY PROTEIN; THROMBOSPONDIN 1; THROMBOSPONDIN 2; VIRUS PROTEIN;

ARTICLE; CELL CULTURE; CONTROLLED STUDY; CORNEA CELL; CORNEA NEOVASCULARIZATION; DENSITOMETRY; DOWN REGULATION; HERPES SIMPLEX KERATITIS; HERPES SIMPLEX VIRUS 1; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MONOLAYER CULTURE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; PROTEIN SYNTHESIS REGULATION; QUANTITATIVE ANALYSIS; VIROGENESIS; VIRUS PARTICLE; VIRUS PATHOGENESIS;

BLOTTING, WESTERN; CELLS, CULTURED; CORNEAL STROMA; DOWN-REGULATION; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FIBROBLASTS; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASES; HERPESVIRUS 1, HUMAN; HUMANS; IMMUNOENZYME TECHNIQUES; THROMBOSPONDIN 1; THROMBOSPONDINS; VIRAL ENVELOPE PROTEINS;

EID: 25444455101     PISSN: 10900535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Liesegang TJ. Herpes simplex virus epidemiology and ocular importance. Cornea 2001; 20:1-13.
2. Tullo A. Pathogenesis and management of herpes simplex virus keratitis. Eye 2003; 17:919-22.
3. Lee P, Wang CC, Adamis AP. Ocular neovascularization: an epidemiologic review. Surv Ophthalmol 1998; 43:245-69.
4. Streilein JW, Dana MR, Ksander BR. Immunity causing blindness: five different paths to herpes stromal keratitis. Immunol Today 1997; 18:443-9.
5. Thomas J, Rouse BT. Immunopathogenesis of herpetic ocular disease. Immunol Res 1997; 16:375-86.
6. Halberstadt M, Machens M, Gahlenbek KA, Bohnke M, Garweg JG. The outcome of corneal grafting in patients with stromal keratitis of herpetic and non-herpetic origin. Br J Ophthalmol 2002; 86:646-52.
7. Philipp W, Speicher L, Humpel C. Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human corneas. Invest Ophthalmol Vis Sci 2000; 41:2514-22.
8. Zheng M, Deshpande S, Lee S, Ferrara N, Rouse BT. Contribution of vascular endothelial growth factor in the neovascularization process during the pathogenesis of herpetic stromal keratitis. J Virol 2001; 75:9828-35.
9. Zheng M, Schwarz MA, Lee S, Kumaraguru U, Rouse BT. Control of stromal keratitis by inhibition of neovascularization. Am J Pathol 2001; 159:1021-9.
10. Lee S, Zheng M, Kim B, Rouse BT. Role of matrix metalloproteinase-9 in angiogenesis caused by ocular infection with herpes simplex virus. J Clin Invest 2002; 110:1105-11.
11. Sottile J. Regulation of angiogenesis by extracellular matrix. Biochim Biophys Acta 2004; 1654:13-22.
12. Chang JH, Gabison EE, Kato T, Azar DT. Corneal neovascularization. Curr Opin Ophthalmol 2001; 12:242-9.
13. Lashgari MS, Friedman HM, Kefalides NA. Suppression of matrix protein synthesis by herpes simplex virus in bovine smooth muscle cells. Biochem Biophys Res Commun 1987; 143:145-51.
14. Ziaie Z, Friedman HM, Kefalides NA. Suppression of matrix protein synthesis by herpes simplex virus type 1 in human endothelial cells. Coll Relat Res 1986; 6:333-49.
15. Kefalides NA, Ziaie Z. Herpes simplex virus suppression of human endothelial matrix protein synthesis is independent of viral protein synthesis. Lab Invest 1986; 55:328-36.
16. London FS, Brinker JM, Ziaie Z, Kefalides NA. Suppression of host mRNA in human smooth muscle cells by a virion competent factor in herpes simplex virus type 1. Lab Invest 1990; 62:189-95.
17. Iruela-Arispe ML, Luque A, Lee N. Thrombospondin modules and angiogenesis. Int J Biochem Cell Biol 2004; 36:1070-8.
18. Adams JC, Lawler J. The thrombospondins. Int J Biochem Cell Biol 2004; 36:961-8.
19. Armstrong LC, Bornstein P. Thrombospondins 1 and 2 function as inhibitors of angiogenesis. Matrix Biol 2003; 22:63-71.
20. Tolsma SS, Volpert OV, Good DJ, Frazier WA, Polverini PJ, Bouck N. Peptides derived from two separate domains of the matrix protein thrombospondin-1 have anti-angiogenic activity. J Cell Biol 1993; 122:497-511.
21. Vailhe B, Feige JJ. Thrombospondins as anti-angiogenic therapeutic agents. Curr Pharm Des 2003; 9:583-8.
22. Gupta K, Gupta P, Wild R, Ramakrishnan S, Hebbel RP. Binding and displacement of vascular endothelial growth factor (VEGF) by thrombospondin: effect on human microvascular endothelial cell proliferation and angiogenesis. Angiogenesis 1999; 3:147-58.
23. Volpert OV, Tolsma SS, Pellerin S, Feige JJ, Chen H, Mosher DF, Bouck N. Inhibition of angiogenesis by thrombospondin-2. Biochem Biophys Res Commun 1995; 217:326-32.
24. Hiscott P, Seitz B, Schlotzer-Schrehardt U, Naumann GO. Immunolocalisation of thrombospondin 1 in human, bovine and rabbit cornea. Cell Tissue Res 1997; 289:307-10.
25. Hiscott P, Sorokin L, Nagy ZZ, Schlotzer-Schrehardt U, Naumann GO. Keratocytes produce thrombospondin 1: evidence for cell phenotype-associated synthesis. Exp Cell Res 1996; 226:140-6.
26. Armstrong DJ, Hiscott P, Batterbury M, Kaye S. Corneal stromal cells (keratocytes) express thrombospondins 2 and 3 in wound repair phenotype. Int J Biochem Cell Biol 2002; 34:588-93.
27. Hiscott P, Armstrong D, Batterbury M, Kaye S. Repair in avascular tissues: fibrosis in the transparent structures of the eye and thrombospondin 1. Histol Histopathol 1999; 14:1309-20.
28. Cursiefen C, Masli S, Ng TF, Dana MR, Bornstein P, Lawler J, Streilein JW. Roles of thrombospondin-1 and -2 in regulating corneal and iris angiogenesis. Invest Ophthalmol Vis Sci 2004; 45:1117-24.
29. Good DJ, Polverini PJ, Rastinejad F, Le Beau MM, Lemons RS, Frazier WA, Bouck NP. A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc Natl Acad Sci U S A 1990; 87:6624-8.
30. Rodriguez-Manzaneque JC, Lane TF, Ortega MA, Hynes RO, Lawler J, Iruela-Arispe ML. Thrombospondin-1 suppresses spontaneous tumor growth and inhibits activation of matrix metalloproteinase-9 and mobilization of vascular endothelial growth factor. Proc Natl Acad Sci U S A 2001; 98:12485-90.
31. Zhu H, Cong JP, Mamtora G, Gingeras T, Shenk T. Cellular gene expression altered by human cytomegalovirus: global monitoring with oligonucleotide arrays. Proc Natl Acad Sci U S A 1998; 95:14470-5.
32. Cinatl J Jr, Bittoova M, Margraf S, Vogel JU, Cinatl J, Preiser W, Doerr HW. Cytomegalovirus infection decreases expression of thrombospondin-1 and -2 in cultured human retinal glial cells: effects of antiviral agents. J Infect Dis 2000; 182:643-51.
33. Hahn W, Ho SH, Jeong JG, Hahn EY, Kim S, Yu SS, Kim S, Kim JM. Viral vector-mediated transduction of a modified thrombospondin-2 cDNA inhibits tumor growth and angiogenesis. Gene Ther 2004; 11:739-45.
34. Allegrini G, Goulette FA, Darnowski JW, Calabresi P. Thrombospondin-1 plus irinotecan: a novel antiangiogenic-chemotherapeutic combination that inhibits the growth of advanced human colon tumor xenografts in mice. Cancer Chemother Pharmacol 2004; 53:261-6.